No, health insurance does not cover medical marijuana. Private plans, employer coverage, Medicare, and Medicaid all treat cannabis as an ineligible expense because it remains a Schedule I controlled substance under federal law. A small group of FDA-approved medications made from cannabis compounds is covered, but the marijuana you buy at a dispensary is not, anywhere in the United States.
Why No Plan Will Pay for It
The Controlled Substances Act places marijuana in Schedule I, the most restrictive category, defined as having no accepted medical use and a high potential for abuse.1Drug Enforcement Administration. Controlled Substance Schedules From there, everything else follows.
The FDA has not approved cannabis as a drug for any disease or condition.2U.S. Food and Drug Administration. FDA and Cannabis: Research and Drug Approval Process Without FDA approval, marijuana has no National Drug Code, which is the identifier pharmacies and insurers use to process reimbursements. No code, no formulary listing, no way to bill.
Terminology matters too. In legal states, doctors don’t prescribe marijuana; they recommend it. Prescriptions require FDA-approved medications from licensed pharmacies, and dispensaries are not pharmacies under federal law. Most insurance plans require medications to come from a licensed pharmacy, which gives them a second, independent reason to deny a cannabis claim.
What Each Type of Plan Actually Does
Medicare Part D plans can only list FDA-approved drugs on their formularies, so cannabis doesn’t qualify.3MACPAC. Strengthening Evidence Under Medicaid Drug Coverage Medicare Advantage plans face the same restriction, and CMS has explicitly listed cannabis products among items that cannot be offered as supplemental benefits for chronically ill enrollees, grouping marijuana with alcohol and tobacco.
Medicaid works the same way. Federal Medicaid reimbursement generally requires FDA approval.4U.S. Department of Health and Human Services Office of Inspector General. One Percent of Drugs With Medicaid Reimbursement Were Not FDA-Approved Several states have floated bills to make Medicaid pay for medical marijuana; none have passed. The structural problem is that Medicaid depends on federal matching funds, and covering a federally illegal substance would put those funds at risk.
Employer-sponsored plans don’t cover it either. Fully insured plans could in theory be required to cover marijuana by state law, but no state has done that. Self-funded employer plans are governed by federal law and have no pathway to cannabis coverage at all. Even the doctor visit to get a recommendation is usually excluded, because the purpose of the appointment is to authorize a federally prohibited substance. Many cannabis-evaluation clinics don’t accept insurance in the first place and charge a flat fee.
The Cannabis-Derived Drugs Insurance Does Cover
A small group of FDA-approved medications derived from or chemically related to cannabis is covered by insurance and appears on standard formularies.5U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)
- Epidiolex is a purified CBD oral solution drawn directly from the cannabis plant. It’s approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients one year and older. It sits in a protected drug class, so Medicare Part D plans are required to cover it, and the manufacturer’s copay assistance program brings most commercially insured patients’ out-of-pocket cost to $0.6EPIDIOLEX. Cost and Coverage
- Marinol and Syndros are synthetic THC (dronabinol) medications approved for AIDS-related appetite loss and chemotherapy-induced nausea. Generic dronabinol appears on many Part D and commercial formularies, often at the lowest cost tier, though prior authorization is usually required.
- Cesamet (nabilone) is a synthetic compound chemically similar to THC, approved for chemotherapy-related nausea.
If your condition matches one of these approvals, ask your doctor whether one of these medications could substitute for what you were hoping medical marijuana would do. Insurance will actually pay.
HSAs, FSAs, and the Medical Expense Deduction
You cannot use a health savings account, flexible spending account, or health reimbursement arrangement to pay for medical marijuana. The IRS says so directly: “You can’t include in medical expenses amounts you pay for controlled substances (such as marijuana) that aren’t legal under federal law, even if such substances are legalized by state law.”7Internal Revenue Service. Publication 502, Medical and Dental Expenses
The same rule blocks the medical expense deduction under Section 213 of the Internal Revenue Code, even if your cannabis costs exceed 7.5% of your adjusted gross income.8Office of the Law Revision Counsel. 26 USC 213 – Medical, Dental, Etc., Expenses One insurer’s eligible-expense list puts it plainly: “Marijuana, even if prescribed by a doctor, is not reimbursable.”9Cigna Healthcare. Which Expenses Are Eligible for HSA, FSA, and HRA Reimbursement
Workers’ Compensation Is the One Real Exception
Workers’ comp is the only insurance category where medical marijuana reimbursement has gained any real ground. Roughly six states now require workers’ comp insurers to reimburse injured workers for medical marijuana when a treating physician deems it necessary. About six other states explicitly prohibit reimbursement. The rest sit in a gray zone with no clear mandate either way.
The pattern usually comes from state courts interpreting workers’ comp statutes and the meaning of “reasonable and necessary” medical treatment. Where reimbursement is required, courts have concluded that state workers’ comp law governs treatment decisions and that federal prohibition doesn’t override the state’s obligation. Where it’s blocked, legislatures have written in explicit exclusions or courts have sided with insurers on the federal conflict.
If you’re an injured worker, the answer depends entirely on your state. Ask a workers’ comp attorney before assuming anything, because the law is still shifting.
What Medical Marijuana Actually Costs Out of Pocket
Since you’re paying for everything yourself, the real question is what to budget. Research on cancer patients using cannabis found a median monthly out-of-pocket cost of roughly $80 to $100. Light users may spend under $25 a month; heavy users or those buying concentrated products can spend several hundred.
The product isn’t the only expense. Plan on:
- An initial physician evaluation, often $100 to $300.
- A state registration or card fee, ranging from nothing to around $200 depending on the state. Some states offer reduced fees for veterans or patients on public assistance.
- Annual renewals in some states for both the card and the physician certification.
Add it up and a medical marijuana patient can easily spend $1,500 to $3,000 or more per year, with no insurance offset and no tax benefit. For patients on Medicaid or fixed incomes, that math can make cannabis inaccessible even where it’s perfectly legal.
How Medical Marijuana Affects Life Insurance
Life insurance is a separate question from health coverage, but it comes up often enough to flag. Most life insurers ask about marijuana use on their applications, and your answer affects your rate class.
The industry has moved away from automatically declining cannabis users or treating all use as equivalent to daily cigarette smoking. Many insurers now evaluate frequency, method, and the underlying condition separately. Occasional users can qualify for non-smoker or even preferred rates at some carriers. Frequent daily users are more likely to be classified as smokers, which can triple premiums. On average, cannabis users in good health pay roughly 35% to 65% more for term life insurance than comparable non-users, and the spread between companies is wide enough that shopping multiple insurers matters more here than in most other scenarios.
What Federal Rescheduling Could Change
In May 2024, the DEA proposed a rule to move marijuana from Schedule I to Schedule III. In December 2025, President Trump issued an executive order directing the attorney general to expedite the process. As of early 2026, the rulemaking is still pending, with a scheduled hearing postponed while a legal challenge is resolved.
If rescheduling is finalized, it would acknowledge that marijuana has accepted medical uses and a lower abuse potential than Schedule I drugs. That sounds like it should open the door to insurance coverage, but the reality is narrower. Reclassification alone would not let doctors prescribe dispensary marijuana the way they prescribe other Schedule III drugs. Cannabis products would still lack FDA approval, standardized dosing, and National Drug Codes, so insurers would still have grounds to exclude them.
What rescheduling could do is remove the IRS barrier. If marijuana is no longer a substance illegal under federal law, the prohibition on HSA, FSA, and medical expense deductions would likely fall away. That alone could save regular users hundreds of dollars a year. Rescheduling would also make it easier for researchers to run the large-scale clinical trials that could eventually lead to FDA approval of specific cannabis formulations, which is the real path to insurance coverage.
For now, the practical answer stands: insurance does not cover medical marijuana, and patients need to budget for the full cost themselves.